United Arab Emirates: Embryonic Stem Cell Research And Legalities Of Destruction Of Foetus

Last Updated: 25 September 2018
Article by STA Law Firm
Most Popular Article in United Arab Emirates, October 2018

Embryonic Stem Cell Research and its Implications for Destruction of Foetus

Embryonic stem cell research is a cause of great contention globally, and the regulation and stigma around such research is and will continue to be a heated topic. In the governance of every country, the murder of another human being is a crime punishable by law, and the removal of embryonic stem cells is the act of causing such stem cells for not developing into a human being. Where is the line is drawn in the sand, at what point is the destruction of an embryo for science murder and when is it not? At what point of conception does a fetus being a human being in the eyes of the law and is granted protection as such.

Common law jurisdictions such as South Africa provide a fiction regarding which the law can grant unborn fetus protection; this is the nasciturus fiction which traces its source from the Roman law. Regarding this legal principle whenever there is a situation which would have been to the advantage of the fetus if she/he was already born, all rights that get conferred on persons that are already born alive, are also consulted on the embryo. The fetus then becomes a legal persona and carries legal capacity from the date of conception.

Embryonic stem cell research in China

In the past, China was without a comprehensive regulatory framework to govern embryonic stem cell research. It has led to a large number of unproven treatments derived from embryonic stem cell research used on the open market. It has created an environment which was not only detrimental to those patients participating in such unproven treatments but also cast doubt on the research of those scientists who were breaking new ground in the stem cell research field.

In 2003, the People's Republic of China's Ministry of Science and Technology and the Ministry of Health released official ethical guidelines for human embryonic stem cell research. The guidelines formally forbid any research targeted at human reproductive cloning and necessitate that the embryos that get utilized for stem cell research come only from:

  1. Spared gamete or blastocyst after in-vitro fertilization procedures;
  2. Fetal cells from accidental, spontaneous or voluntary selected abortions;
  3. A blastocyst or parthenogenetic split blastocysts obtained by somatic nuclear transfer technology; or
  4. Germ cells voluntarily donated.

In January 2012, the Chinese government implemented a ban on unapproved stem-cell therapies and a temporary moratorium on new clinical trials. With this ban, the government promised to establish a much-needed regulatory framework for future research.

However, regardless of the regulations put in place by the government, rogue research facilities continued to operate. The only impact that was evident was a restraint on stem-cell scientists with compelling research agendas.

In 2015, the Chinese government brought into effect more stringent regulations on embryonic stem cell research, which they believed would curb the use of unproven treatments. These regulations include:

  • 'obtaining patients' informed consent;
  • Using clinical-grade stem cells that have been authorized by an independent body;
  • Stem cell clinical studies will only be carried out at authorized hospitals; and
  • No costs involved for recipients of stem cell research-based treatment."

Presently, the Chinese Ministry of Science and Technology's aim for China is to become one of the leading countries in the field of embryonic stem cell research. The nation is supplying institutes conducting such research with funds from multiple sources.

Guidelines on Chinese Embryo Stem Cell Research

The director of the Chinese Society of Medical Ethics, Professor Benfu Li laid down the following principles to be abided by when conducting embryonic stem cell research in China:

  1. The Principle of Respect – an embryo must get considered as human biological life and as such demands a specific value – this requires that a fetus cannot be damaged or controlled without enough reason. The medical potential of human embryonic stem cell research is so vast that such research should undoubtedly be permitted and supported.
  2. The Principle of Informed Consent – donors, must be informed of all aspects of the research before such a donation. They must consent to all procedures to be undertaken during the investigation, and such consent must be kept a secret.
  3. The Principle of Safety and Utility – this principle determines that before any research conducted with human embryonic stem cells, it must have been tested on animals to avoid bringing damage to patients and donors alike. The study will not be used in clinical medicine until proven that experiments on animals are safe and useful.
  4. The Principle of Non-commercialisation – this principle prohibits the buying and selling of gametes, embryos and fetal tissue. If such buying and selling were not banned, it could lead to the exploitation of donors.

As was discussed above, the ethical concerns regarding embryonic stem cell research spark much debate around the world. The use and destruction of the embryo for research purposes is a controversial part of the research process. However, in China, this is not the case. Most Chinese citizens view the embryo as not containing any inherent moral value.

The Chinese citizens have followed a Confucian way of life for two millennia. According to a Confucian view, "a person being with birth; a person is an entity that has a body or shape and psyche, and has a rational, emotional and social-relational capacity for a lifetime of learning and innovation."

This way of thinking, therefore, results in the Chinese population viewing a human embryo as not having the characteristics of a human being and thus cannot be equated morally to a person requiring the protection of the law.

Regulation in the UAE

In the majority of the countries in the Middle East, there is no regulation for stem cell research and the scientists, and research institutes mostly rely on religious decrees. The UAE does not have any national legal framework or rules governing Embryonic Stem Cell research. However, as per the Sharia law, an individual will be required to pay 10% of the blood money even for accidentally killing a fetus. This principle of Sharia law was applied by The Dubai Traffic Court of First Instance where it fined a Lebanese woman for accidentally killing a nine-month embryo in a traffic accident.1 In another incident, a man was convicted for killing his wife who was two months pregnant and unborn child. The Abu Dhabi Criminal Court of First Instance's judgment was also upheld by the Appellate Court too upheld the decision.2 Moreover, in 2012, the Dubai Health Authority ordered a stem-cell company to stop operations after it discovered to be promoting a treatment which is linked with the death of two children.3


1 https://gulfnews.com/news/uae/transport/mother-convicted-of-killing-foetus-in-traffic-accident-1.67532

2 https://www.thenational.ae/uae/courts/death-sentence-upheld-in-pregnant-woman-s-murder-1.494069

3 https://www.thenational.ae/uae/embryo-research-a-moral-and-ethical-minefield-1.362764

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

In association with
Related Topics
Related Articles
Up-coming Events Search
Font Size:
Mondaq on Twitter
Mondaq Free Registration
Gain access to Mondaq global archive of over 375,000 articles covering 200 countries with a personalised News Alert and automatic login on this device.
Mondaq News Alert (some suggested topics and region)
Select Topics
Registration (please scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions